Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
EUCR was delisted on the 26th of April, 2023.
34 hedge funds and large institutions have $49.6M invested in Eucrates Biomedical Acquisition Corp. Ordinary Shares in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
10% more funds holding
Funds holding: 31 → 34 (+3)
4% more capital invested
Capital invested by funds: $47.8M → $49.6M (+$1.81M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$780K |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$765K |
| 3 |
SIA
SkyView Investment Advisors
Shrewsbury,
New Jersey
|
+$648K |
| 4 |
D.E. Shaw & Co
New York
|
+$533K |
| 5 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
+$324K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$985K |
| 2 |
EAM
Exos Asset Management
New York
|
-$103K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$98K |
| 4 |
SC
Shay Capital
New York
|
-$69.6K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$50.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
26
Saba Capital Management
New York
| $263K | +$262K | +26,874 | New |
|
|
MF
27
Magnetar Financial
Evanston,
Illinois
| $206K | +$89.9K | +9,224 | +78% |
|
28
T. Rowe Price Associates
Baltimore,
Maryland
| $199K | – | – | – |
|
|
AC
29
Athanor Capital
New York
| $118K | -$7.41K | -760 | -6% |
|
|
DFCM
30
Dark Forest Capital Management
San Juan,
Puerto Rico
| $103K | +$102K | +10,509 | New |
|
31
Morgan Stanley
New York
| $38K | – | – | – |
|
32
UBS Group
Zurich,
Switzerland
| $24K | -$12.7K | -1,299 | -34% |
|
|
WCMNY
33
Westchester Capital Management (New York)
Valhalla,
New York
| $11K | +$10.7K | +1,100 | New |
|
|
CIM
34
Cowen Investment Management
New York
| $489 | – | – | – |
|
|
GPCM
35
Granite Point Capital Management
Boston,
Massachusetts
| – | -$985K | -100,000 | Closed |
|
|
EAM
36
Exos Asset Management
New York
| – | -$103K | -10,485 | Closed |
|
|
PAM
37
Panagora Asset Management
Boston,
Massachusetts
| – | -$98K | -9,922 | Closed |
|
EUCR Hedge Fund Activity: Q3 2021 in Review
34 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) for Q3 2021, worth a combined $49.6M — up 3.8% from $47.8M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new EUCR positions and 3 closed out — a net gain of 3 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Millennium Management, adding an estimated $780K. The largest seller was Granite Point Capital Management, exiting entirely with an estimated $985K sold.
- 34 institutional investors held Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) as of Q3 2021, up from 31 in Q2 2021.
- Funds reported $49.6M of Eucrates Biomedical Acquisition Corp. Ordinary Shares stock for Q3 2021, up 3.8% quarter-over-quarter.
- 6 funds opened new Eucrates Biomedical Acquisition Corp. Ordinary Shares positions in Q3 2021 and 3 closed out, a net change of +3 holders.
- The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares buyer in Q3 2021 was Millennium Management, an estimated $780K added.
- The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares seller in Q3 2021 was Granite Point Capital Management, an estimated $985K sold.
Based on aggregated 13F filings for Q3 2021.